JAWAD SARWAR
Allopathic & Osteopathic Physicians|Internal Medicine HOUSTON, TX NPI 1376580787
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine TX Novo Nordisk AS All categories
General Payments — all program years on this page
$973.05
- Category: General Payments
- Program years: PY2018–2024
- Record count: 50
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $207.08 across 7 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $207.08 | 7 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $90.19 | 1 |
| Lilly USA, LLC | $29.42 | 2 |
| Acerta Pharma LLC | $25.28 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $23.52 | 1 |
| Exact Sciences Corporation | $20.04 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.63 | 1 |
By program year
Records — PY2024 (7)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1087264045 | Novartis Pharmaceuticals Corporation | $23.52 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1096669267 | Novo Nordisk Inc | $90.19 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105668947 | AstraZeneca Pharmaceuticals LP | $25.28 | 06/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1114875368 | Exact Sciences Corporation | $20.04 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1117985306 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.63 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1135033942 | Lilly USA, LLC | $14.60 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1135048996 | Lilly USA, LLC | $14.82 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.